Skip to main content

Table 2 Tumor size changes in melanoma patients (Ipilimumab-refractory melanoma (KEYNOTE -002))

From: Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

  Number of Prior Line of Therapy Received
1 2 +
(2L) (3L+)
n Median Mean Standard Deviation n Median Mean Standard Deviation
Pembrolizumab arm
 % of Early Tumor Size Changes (~Week 12) 78 −7.4 −10.0 31.3 200 −0.1 −2.4 43.1
 Best % of Tumor Size Changes 78 −11.2 −23.5 43.2 200 −9.4 −16.0 53.5